TARA logo

PROTARA THERAPEUTIC INC

TARANASDAQ
🏆 #3772 by market capEarnings Oct 29US Equity
$2.49▲ $0.02 (+0.81%)
Pre-market · at close
🔔
Track TARA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.8%
7d▲ 2.7%
14d▲ 4.2%
30d▼ 22.8%
ytd▼ 53.3%
1y▼ 52.1%
🏦Market Cap
$147M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
44
Weak

Trading Snapshot

Day Range
$2.37 – $2.52
52-Week Range
$2.28 – $7.82
Volume (shares)
61,937
Avg Volume (shares)
—
Shares Outstanding
59.1M
Next Earnings
2026-10-29

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-1.8
P/S Ratio
0.0x
EPS (TTM)
$-1.15
Dividend Yield
0.00%
Dilution (1yr)
+74.2%
TARA logo

PROTARA THERAPEUTIC INC

TARA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$65M▲ +31.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$56M▲ +57.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.0M▲ +74.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$46M▼ −$112M YoY
StockOtter · stockotter.space

About PROTARA THERAPEUTIC INC

Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Ratings

ⓘ
Consensus
Buy
14 analysts
Strong Buy3
Buy10
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.